[Federal Register Volume 79, Number 109 (Friday, June 6, 2014)]
[Notices]
[Pages 32743-32744]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-13097]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
RNA Splicing Inhibitors To Treat Cancers
Description of Technology: Vemurafenib is a B-Raf enzyme inhibitor
that causes cell death in melanoma tumor cells that possess a mutated
B-Raf protein (V600E BRAF mutation); however, patients rapidly develop
resistance. One mechanism for acquired resistance of these patients to
BRAF inhibitors has been found to be mediated by the existence of BRAF
(V600E) splicing variants that possess structural changes in BRAF that
confer insensitivity to BRAF inhibitors.
Researchers at the National Cancer Institute have discovered that
RNA splicing inhibitors can block the growth of vemurafenib-resistant
tumors. Further, the researchers have also found that other types of
tumors that possess BRAF splicing isoforms are susceptible to RNA
splicing inhibitors.
Available for licensing are methods of using RNA splicing
inhibitors to treat tumors, including melanomas, and methods to detect
tumors that possess certain BRAF splicing isoforms susceptible to RNA
splicing inhibitors.
Potential Commercial Applications: Therapeutic agents to treat
tumors.
Competitive Advantages: No discernible toxicity in mice.
Development Stage: Early-stage; In vitro data available; In vivo
data available (animal).
Inventors: Thomas A. Misteli and Maayan Salton-Morgenstern (NCI).
Intellectual Property: HHS Reference No. E-065-2014/0--U.S.
Application No. 61/974,378 filed 02 Apr 2014.
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
[email protected].
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
the development of RNA splicing modulators as therapeutic agents in
cancer. For collaboration opportunities, please contact John D. Hewes,
Ph.D. at [email protected].
Treatment of Chronic Kidney Disease With Synthetic Amphipathic Peptides
Description of Technology: The invention is directed to treatment
of chronic kidney disease by administering a synthetic, amphipathic
helical peptide known as 5A-37pA, and novel derivatives thereof.
Scientists at NIDDK have demonstrated that invention peptides
antagonize activity of a particular scavenger receptor known as CD36.
Using an in vivo model, NIDDK scientists have shown that invention
peptides slowed progression of chronic kidney disease and can
potentially be utilized as a therapeutic treatment.
Additionally, certain invention peptides bind selectively to CD36
with high specificity over other homologous scavenger receptors. Thus,
invention peptides can be utilized as a research tool to further
evaluate the complex etiology of chronic kidney disease.
5A-37pA, and derivatives thereof, are peptide mimetic of
apolipoprotein A-1. These peptides have been described in NIH owned
patents and/or patent applications (see, for example, U.S. Patent Nos.
7,572,771 and 8,071,746 and 8,148,323). Use of these peptides, as well
as the novel peptides of this invention, for the treatment of kidney
diseases is currently available for licensing.
Potential Commercial Applications: Therapeutic; Research Tool.
Competitive Advantages: Selective antagonist of CD36 activity;
Specific binding to CD36 over other scavenger receptors.
Development Stage: Early-stage; In vitro data available; In vivo
data available (animal).
[[Page 32744]]
Inventors: Ana C. Souza (NIDDK), Peter S. Yuen (NIDDK), Robert A.
Star (NIDDK), Alexander V. Bocharov (CC), Alan Remaley (NHLBI), Thomas
Eggerman (NIDDK).
Intellectual Property: HHS Reference No. E-743-2013/0--U.S.
Application No. 61/890,585 filed 14 Oct 2013.
Related Technology: HHS Reference No. E-114-2004/0.
Licensing Contact: Lauren Nguyen-Antczak, Ph.D., J.D.; 301-435-
4074; [email protected].
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Treatment of
Chronic Kidney Disease with 5A-37pA and Derivatives Thereof. For
collaboration opportunities, please contact Marguerite Miller at
[email protected] or 301-496-9003.
Novel Anti-HIV Proteins From Coral Reefs
Description of Technology: The subject invention describes
Cnidarins as a novel class of highly potent proteins capable of
blocking the HIV virus from penetrating T-cells. Cnidarins were found
in a soft coral collected in waters off Australia's northern coast.
Cnidarins can block virus fusion/entry but do not block viral
attachment. In addition, Cnidarins do not have lectin-like activity and
therefore possibly a unique mechanism of action. Thus, Cnidarins may
represent important new leads for HIV microbicides or for systemic
therapeutics for HIV.
Potential Commercial Applications: Microbicide; Therapeutic;
Research tool.
Competitive Advantages: High potency against HIV; Novel chemical
composition; Family of related proteins; Unique mechanism of action.
Development Stage: Early-stage; In vitro data available; Prototype.
Inventors: Barry O'Keefe, James McMahon, Koreen Ramessar, Chang-yun
Xiong (all of NCI).
Intellectual Property: HHS Reference No. E-295-2012/0--U.S.
Provisional Patent Application No. 61/925,347 filed 09 Jan 2014.
Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301-435-5606;
[email protected].
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
large-scale recombinant production of cnidarins and evaluation of their
broader antiviral activity as well as additional pre-clinical studies.
For collaboration opportunities, please contact John D. Hewes, Ph.D. at
[email protected].
Dated: June 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-13097 Filed 6-5-14; 8:45 am]
BILLING CODE 4140-01-P